Background And Objective: The current guidelines on hypoparathyroidism offer a model for treating patients but do not cover real-world situations or patient diversity. Given the lack of data regarding hypoparathyroidism, a Delphi panel was convened in Spain to establish consensus in defining the characteristics of patients with chronic hypoparathyroidism not adequately controlled with conventional treatment, as well as to investigate patterns of management.
Material And Methods: A presentation matrix provided a framework for characterizing inadequately controlled chronic hypoparathyroidism, based on four predefined patient groups: group 1 (normal biochemical levels and the patient feeling well); group 2 (abnormal biochemical levels and the patient feeling well); group 3 (normal biochemical levels and the patient feeling unwell); and group 4 (abnormal biochemical levels and the patient feeling unwell). Based on Likert scales (scored 1-9), the experts were asked to state their agreement/disagreement with the characteristics of patients with chronic hypoparathyroidism, including demographic data, family history, comorbidities, biochemical values, symptoms and quality of life. Consensus was achieved when ≥66% of the respondents were in agreement.
Results: Consensus was achieved on the importance of assessing demographic data and comorbidities (e.g., renal complications) in groups 2, 3 and 4; family medical history in groups 2 and 3; biochemical parameters (e.g., calcemia/urinary calcium excretion) in groups 2 and 4; and clinical symptoms and quality of life in groups 3 and 4. Consensus was also reached regarding the maintenance of several biochemical parameters and the need for personalized treatment and training in symptoms and complications.
Conclusions: The Spanish expert panel reached consensus defining key disease parameters and factors of importance for characterizing and treating patients with inadequately controlled chronic hypoparathyroidism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.endien.2021.08.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Albumin adjustment of total serum calcium - is it worth doing?].
Probl Endokrinol (Mosk)
November 2024
Calcium is the most abundant mineral in the human body. About 99% of calcium is deposited in the bones in the form of hydroxyapatite and only 1% is located in the intracellular and extracellular fluid. Ionized calcium, which makes up about 50% of the total amount of circulating calcium, is biologically active; the remaining percentage is bound to plasma proteins (40%, of which albumin accounts for 90%, and globulins for 10%), or is in complex with anions (10%) such as citrate, lactate, bicarbonate, phosphate.
View Article and Find Full Text PDF[Endocrinology : what's new in 2024].
Rev Med Suisse
January 2025
Unité d'endocrinologie, Service d'endocrinologie, diabétologie et métabolisme,Département de médecine, Centre hospitalier universitaire vaudois, 1011 Lausanne.
In this article, we look at a selection of recent developments in various areas of endocrinology. We focus on advances in endocrine pharmacotherapy and endocrine surgery, addressing several areas: a) the thyroid safety of Glucagon-Like Peptide-1 (GLP1) analogues; b) the efficacy of adrenal surgery for mild autonomous cortisol secretion; c) crinecerfont in the management of congenital adrenal hyperplasia in adults and children; d) paltusotin as a novel oral therapy for acromegaly and e) TransCon PTH (palopegteriparatide) as a novel therapy for chronic hypoparathyroidism.
View Article and Find Full Text PDFDiagnosing Hypoparathyroidism, Sensorineural Deafness, and Renal Dysplasia Syndrome and a Novel Variant.
JCEM Case Rep
January 2025
Division of Endocrinology, Diabetes and Metabolism, The Ohio State University Wexner Medical Center and Arthur G. James Comprehensive Cancer Center, Columbus, OH 43210, USA.
Hypoparathyroidism (hypoPTH), sensorineural deafness, and renal dysplasia (HDR) syndrome is a rare autosomal dominant condition with approximately 200 cases published. HDR syndrome is caused by variants of GATA binding protein 3 gene (), which encodes a transcription factor, with multiple types of variants reported. We present the case of a 76-year-old woman who was diagnosed with hypoPTH when she was aged 40 years and transferred care to our institution.
View Article and Find Full Text PDFHypoparathyroidism: Similarities and differences between Western and Eastern countries.
Osteoporos Int
January 2025
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Backgroud: Hypoparathyroidism (hypoPT) is characterized by acute and chronic complications due to insufficient parathyroid hormone (PTH) production or action. Several management guidelines have been developed, but mostly based on evidence from Western countries. Data from Eastern countries have not been systematically compared with those from Western countries.
View Article and Find Full Text PDF[DiGeorge syndrome with 22q11.2 deletion in a patient of Rarámuri ethnicity].
Rev Alerg Mex
December 2024
Departamento de Inmunología, Hospital Infantil de Especialidades de Chihuahua; Facultad de Medicina y Ciencias Biomédicas, Universidad Autónoma de Chihuahua.
Background: 22q11 deletion syndrome consists of a variable grouping of phenotypic features and immunological defects secondary to the loss of genetic material located in the 22q11.2 band. The 22q11 deletion spectrum encompasses different syndromes related to the same etiology and with overlapping anomalies, including DiGeorge syndrome, velocardiofacial syndrome, among others.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!